Various other targets are being explored for haematological malignancies, including CD37 for patients with relapsed and refractory diffuse large B cell lymphoma with naratuximab emtansine, CD138 with indatuximab ravtansine for multiple myeloma, CD19 with coltuximab mertansine for diffuse large B cell lymphoma and acute lymphocytic leukaemia, CD56 with lorvotuzumab mertansine for CD56 expressing haematological malignancies, and CD22 with pinatuzumab vedotin for diffuse large B cell lymphoma and follicular non-Hodgkin lymphoma [131]. Here, CD19 is linked to diffuse large B-cell lymphoma.